Literature DB >> 7563195

Chemosensitizers to overcome and prevent multidrug resistance?

U A Germann, M W Harding.   

Abstract

Mesh:

Substances:

Year:  1995        PMID: 7563195     DOI: 10.1093/jnci/87.21.1573

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  5 in total

1.  Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: high-dose oral tamoxifen and dexverapamil.

Authors:  G Weinländer; G Kornek; M Raderer; M Hejna; C Tetzner; W Scheithauer
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Prediction of P-glycoprotein inhibitors with machine learning classification models and 3D-RISM-KH theory based solvation energy descriptors.

Authors:  Vijaya Kumar Hinge; Dipankar Roy; Andriy Kovalenko
Journal:  J Comput Aided Mol Des       Date:  2019-11-19       Impact factor: 3.686

3.  The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents.

Authors:  Trudy H Grossman; Carolyn M Shoen; Steven M Jones; Peter L Jones; Michael H Cynamon; Christopher P Locher
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

Review 4.  Novel strategies to prevent the development of multidrug resistance (MDR) in cancer.

Authors:  Jinglu Wang; Nicole Seebacher; Huirong Shi; Quancheng Kan; Zhenfeng Duan
Journal:  Oncotarget       Date:  2017-07-12

5.  Reduction of breast tumor drug resistance by 2,3,5,4'-tetrahydroxystilbene for exhibition synergic chemotherapeutic effect.

Authors:  Yao-Yuan Chang; Hung-Jun Lin; Ling-Chi Hsiao; Yu-Feng Lin; Chih-Sheng Chang; Der-Zen Liu
Journal:  PLoS One       Date:  2021-12-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.